ArticleFrontiers in pharmacology2025

A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy.

Shizhu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.